Transcranial laser therapy attenuates amyloid-β peptide neuropathology in amyloid-β protein precursor transgenic mice.

Transcranial laser therapy (TLT) was tested for efficacy in a mouse model of Alzheimer's disease (AD) using a near-infrared energy laser system. TLT is thought to stimulate ATP production, increase mitochondrial activity, and help maintain neuronal function. Studies were performed to determine the effect of TLT in an amyloid-β protein precursor (AβPP) transgenic mouse model. TLT was administered 3 times/week at various doses, starting at 3 months of age, and was compared to a control group (no laser treatment). Treatment was continued for a total of six months. Animals were examined for amyloid load, inflammatory markers, brain amyloid-β (Aβ) levels, plasma Aβ levels, cerebrospinal fluid Aβ levels, soluble AβPP (sAβPP) levels, and behavioral changes. The numbers of Aβ plaques were significantly reduced in the brain with administration of TLT in a dose-dependent fashion. Administration of TLT was associated with a dose-dependent reduction in amyloid load. All TLT doses mitigated the behavioral effects seen with advanced amyloid deposition and reduce the expression of inflammatory markers in the AβPP transgenic mice. All TLT doses produced an increase in sAβPPα and a decrease in CTFβ levels consistent with inhibition of the β-secretase activity. In addition, TLT showed an increase in ATP levels, mitochondrial function, and c-fos suggesting an overall improvement in neurological function. These studies suggest that TLT is a potential candidate for treatment of AD.

[1]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[2]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[3]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Selkoe,et al.  Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide , 1993, Cell.

[5]  The molecular genetics of Alzheimer's disease , 1994 .

[6]  L A Hansen,et al.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias. , 1994, Archives of neurology.

[7]  F. Checler.  Processing of the β‐Amyloid Precursor Protein and Its Regulation in Alzheimer's Disease , 1995 .

[8]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[9]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[10]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[11]  Tiina I. Karu,et al.  Mechanisms of interaction of monochromatic visible light with cells , 1996, European Conference on Biomedical Optics.

[12]  Joseph D. Buxbaum,et al.  Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.

[13]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[14]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[15]  Raymond J. Lanzafame,et al.  Low Level Laser Therapy: Clinical Practice and Scientific Background , 1999 .

[16]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[17]  B. Strooper,et al.  Proteolytic processing and cell biological functions of the amyloid precursor protein. , 2000, Journal of cell science.

[18]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Tiina I. Karu,et al.  Mechanisms of low-power laser light action on cellular level , 2000, European Conference on Biomedical Optics.

[20]  M. Wong-Riley,et al.  Light-emitting diode treatment reverses the effect of TTX on cytochrome oxidase in neurons , 2001, Neuroreport.

[21]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[22]  U. Oron,et al.  Long-term effect of low energy laser irradiation on infarction and reperfusion injury in the rat heart. , 2001, Journal of applied physiology.

[23]  R. Shofti,et al.  Low-Energy Laser Irradiation Reduces Formation of Scar Tissue After Myocardial Infarction in Rats and Dogs , 2001, Circulation.

[24]  Amir Oron,et al.  Attenuation of infarct size in rats and dogs after myocardial infarction by low‐energy laser irradiation , 2001, Lasers in surgery and medicine.

[25]  D. Selkoe.  Presenilin, Notch, and the genesis and treatment of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jun-tao Guo,et al.  Inflammation-Dependent Cerebral Deposition of Serum Amyloid A Protein in a Mouse Model of Amyloidosis , 2002, The Journal of Neuroscience.

[27]  Semion Rochkind,et al.  Transplantation of embryonal spinal cord nerve cells cultured on biodegradable microcarriers followed by low power laser irradiation for the treatment of traumatic paraplegia in rats , 2002, Neurological research.

[28]  Uri Oron,et al.  Low-energy laser irradiation promotes the survival and cell cycle entry of skeletal muscle satellite cells. , 2002, Journal of cell science.

[29]  B. Martoglio,et al.  Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic Protease , 2002, Science.

[30]  Noel T. Whelan,et al.  Therapeutic photobiomodulation for methanol-induced retinal toxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Xi Chen,et al.  RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice , 2004, The EMBO journal.

[32]  A. J. Gandolfi,et al.  Human liver quality is a dominant factor in the outcome of in vitro studies , 2004, Cell Biology and Toxicology.

[33]  P. Lapchak,et al.  Transcranial Infrared Laser Therapy Improves Clinical Rating Scores After Embolic Strokes in Rabbits , 2004, Stroke.

[34]  Luis De Taboada,et al.  Mechanisms of action of light therapy for stroke and acute myocardial infarction. , 2004, Mitochondrion.

[35]  Uri Oron,et al.  Protection of skeletal muscles from ischemic injury: low-level laser therapy increases antioxidant activity. , 2005, Photomedicine and laser surgery.

[36]  R. Waynant,et al.  Light promotes regeneration and functional recovery and alters the immune response after spinal cord injury , 2005, Lasers in surgery and medicine.

[37]  Amir Oron,et al.  Transcranial application of low‐energy laser irradiation improves neurological deficits in rats following acute stroke , 2006, Lasers in surgery and medicine.

[38]  Jieli Chen,et al.  Low-Level Laser Therapy Applied Transcranially to Rats After Induction of Stroke Significantly Reduces Long-Term Neurological Deficits , 2006, Stroke.

[39]  Marc Fisher,et al.  Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1) , 2007, Stroke.

[40]  Amir Oron,et al.  low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. , 2007, Journal of neurotrauma.

[41]  A. Bielawska,et al.  JNK3 Signaling Pathway Activates Ceramide Synthase Leading to Mitochondrial Dysfunction* , 2007, Journal of Biological Chemistry.

[42]  S. Hickman,et al.  Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice , 2008, The Journal of Neuroscience.

[43]  Jackson Streeter,et al.  Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits , 2008, Stroke.

[44]  I. Verma,et al.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.

[45]  G. Siciliano,et al.  The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. , 2009, Current Alzheimer research.

[46]  Marc Fisher,et al.  Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke , 2009, Stroke.

[47]  Jackson Streeter,et al.  810 nm Wavelength light: An effective therapy for transected or contused rat spinal cord , 2009, Lasers in surgery and medicine.

[48]  C. Peters,et al.  Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. , 2009, Biochemical and biophysical research communications.

[49]  George Perry,et al.  Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.

[50]  W. Markesbery,et al.  Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[51]  Paul A. Lapchak,et al.  Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5′-triphosphate (ATP) content following embolic strokes in rabbits , 2010, Brain Research.